Enliven Q3 net loss $23.2M; ELVN-001 Phase 1 MMR rate 44% by 24 weeks

Enliven Therapeutics, Inc.

2024-Q3 EPS reported -$1.43

Cash $291.8M as of Sept 30, 2024; runway into late 2026.
Net loss $23.2M (Q3 2024) vs $20.8M (Q3 2023); R&D expenses $21.3M.
ELVN-001 Phase 1: cumulative MMR 44% (8/18) by 24 weeks; no dose reductions at ≥40 mg due to TRAEs.
Plan to report additional ELVN-001 data in 2025 with ~60-100 patients across lines of therapy.
ELVN-002 trials in HER2+ MBC and CRC ongoing; data anticipated in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.